Phase II Trial of Lung Chemoemobolization

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a

Trial Details

NCT ID

NCT05672108

Phase

PHASE2

Sponsor

City of Hope Medical Center

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Computed Tomography
Ethiodized Oil
Mitomycin
Transarterial Chemoembolization
Tris-acryl Gelatin Microspheres

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient c…
Lung-dominant disease (majority of active tumor volume is in the chest)
At least 18 years old

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →